Hypoxia-dependent retinal toxicity of bioreductive anticancer prodrugs in mice

Toxicology and Applied Pharmacology

Volumn 163, Issue 1, 2000, Pages 50-59

  Lee, Alan E ^a   Wilson, William R ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

AQ4N; Bioreductive drugs; CI 1010; Hypoxia; Photoreceptors; Porfiromycin; Retina; SN 23816; SN 25341; Tirapazamine

Indexed keywords

1 (2 BROMOETHYLAMINO) 3 (2 NITRO 1 IMIDAZOLYL) 2 PROPANOL; ALKYLATING AGENT; ANTHRAQUINONE DERIVATIVE; ANTHRAQUINONE N OXIDE; ANTINEOPLASTIC AGENT; CARBOGEN; CARBON DIOXIDE; CHLORMETHINE DERIVATIVE; NITROIMIDAZOLE DERIVATIVE; OXYGEN; PORFIROMYCIN; PRODRUG; QUINONE DERIVATIVE; SN 23816; SN 25341; TIRAPAZAMINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL LOSS; CONTROLLED STUDY; DOSE RESPONSE; FEMALE; HYPOXIA; MORPHOMETRICS; MOUSE; NONHUMAN; OXYGEN BREATHING; PHOTORECEPTOR CELL; RETINA DISEASE; TIME;

EID: 0034652379     PISSN: 0041008X     EISSN: None     Source Type: Journal    
DOI: 10.1006/taap.1999.8834     Document Type: Article

References (61)

1. Ahmed J., Braun R. D., Dunn R., Linsenmeier R. A. Oxygen distribution in the macaque retina. Invest. Opthalmol. Vis. Sci. 34:1993;516-521.
2. Bill A. Circulation in the eye. Renkin E. M., Michel C. C. Handbook of Physiology. The Cardiovascular System IV. 1984;1001 American Physiology Society, Bethesda.
3. Braun R. D., Linsenmeier R. A. Retinal oxygen tension and the electroretinogram during arterial occlusion in the cat. Invest. Ophthalmol. Vis. Sci. 36:1995;523-541.
4. Braun R. D., Linsenmeier R. A., Goldstick T. K. Oxygen consumption in the inner and outer retina of the cat. Invest. Ophthalmol. Vis. Sci. 36:1995;542-554.
5. Breider M. A., Altrogge D. M., Gough A. W. Effects of light intensity and retinal pigmentation on nitro-imidazole-induced retinal degeneration in rats. Toxicol. Pathol. 24:1996;793.
6. Breider M. A., Pilcher G. D., Graziano M. J., Gough A. W. Retinal degeneration in rats induced by CI-1010, a 2-nitroimidazole radiosensitizer. Toxicol. Pathol. 26:1998a;234-239.
7. Breider M. A., Ulloa H. M., Pegg D. G., Gough A. W. Nitro-imidazole radiosensitizer-induced toxicity in cynomolgus monkeys. Toxicol. Pathol. 26:1998b;651-656.
8. Brizel D. M., Scully S. P., Harrelson J. M., Layfield L. J., Bean J. M., Prosnitz L. R., Dewhirst M. W. Tumor oxygenation predicts for the likelihood of distant metastases in human soft tissue sarcoma. Cancer Res. 56:1996;941-943.
9. Brizel D. M., Sibley G. S., Prosnitz L. R., Scher R. L., Dewhirst M. W. Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck. Int. J. Radiat. Oncol. Biol. Phys. 38:1997;285-289.
10. Brown J. M. SR 4233 (tirapazamine): A new anticancer drug exploiting hypoxia in solid tumours. Br. J. Cancer. 67:1993;1163-1170.
11. Brown J. M., Giaccia A. J. The unique physiology of solid tumors: Opportunities (and problems) for cancer therapy. Cancer Res. 58:1998;1408-1416.
12. Brown J. M., Lemmon M. J. Potentiation by the hypoxic cytotoxin SR 4233 of cell killing produced by fractionated irradiation of mouse tumors. Cancer Res. 50:1990;7745-7749.
13. Brown J. M., Siim B. G. Hypoxia specific cytotoxins in cancer therapy. Semin. Radiat. Oncol. 6:1996;22-36.
14. Bush R. S., Jenkin R. D. T., Allt W. E. C., Beale F. A., Bean H., Dembo A. J., Pringle J. F. Definitive evidence for hypoxic cells influencing cure in cancer therapy. Br. J. Cancer. 37:1978;302-306.
15. Claffey K. P., Robinson G. S. Regulation of VEGF/VPF expression in tumor cells: Consequences for tumor growth and metastasis. Cancer Metastasis Rev. 15:1996;165-176.
16. Cole S., Stratford I. J., Fielden E. M., Adams G. E., Leopold W., Elliott W., Suto M., Sebolt-Leopold J. Dual function nitroimidazoles less toxic than RSU 1069: Selection of candidate drugs for clinical trial (RB 6145 and/or PD 130908). Int. J. Radiat. Oncol. Biol. Phys. 22:1992;545-548.
17. Denny W. A., Wilson W. R., Hay M. P. Recent developments in the design of bioreductive drugs. Br. J. Cancer. 74:1996;S32-S38.
18. Dorie M. J., Brown J. M. Tumor-specific, schedule-dependent interaction between tirapazamine (SR 4233) and cisplatin. Cancer Res. 53:1993;4633-4636.
19. Graeber T. G., Osmanian C., Jacks T., Housman D. E., Koch C. J., Lowe S. W., Giaccia A. J. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature. 379:1996;88-91.
20. Greenwood J. Mechanisms of blood-brain barrier breakdown. Neuroradiol. 33:1991;95-100.
21. Haffty B. G., Son Y. H., Wilson L. D., Papac R., Fischer D., Rockwell S., Sartorelli A. C., Ross D., Sasaki C. T., Fischer J. J. Bioreductive alkylating agent porfiromycin in combination with radiation therapy for the management of squamous cell carcinoma of the head and neck. Radiat. Oncol. Invest. 5:1997;235-245.
22. Höckel M., Schlenger K., Aral B., Mitze M., Schaffer U., Vaupel P. Association between tumor hypoxia and malignant progression in advanced cancers of the uterine cervix. Cancer Res. 56:1996;4509-4515.
23. Horsman M. R., Chaplin D. J., Brown M. J. Tumor radiosensitization by nicotinamide: A result of improved perfusion and oxygenation. Radiat. Res. 118:1989;139-150.
24. Hughes C. S., Irvin C. G., Rockwell S. Effect of deficiences in DNA repair on the toxicity of mitomycin C and porfiromycin to CHO cells under aerobic and hypoxic conditions. Cancer Commun. 3:1991;29-35.
25. Jenkins T. C., Naylor M. A., O'Neill P., Threadgill M. D., Cole S., Stratford I. J., Adams G. E., Fielden M., Suto M. J., Stier M. A. Synthesis and evaluation of α[[(2-haloethyl)amino]methyl]-2-nitro-1H-imidazole-1-ethanols as prodrugs of α-[(1-aziridinyl)methyl]-2-nitro-1H-imidazole-1-ethanol (RSU-1069) and its analogues which are radiosensitizers and bioreductively activated cytotoxins. J. Med. Chem. 33:1990;2603-2610.
26. Koch C. J. Unusual oxygen concentration dependence of toxicity of SR 4233, a hypoxic cell toxin. Cancer Res. 53:1993;3992-3997.
27. Linsenmeier R. A. Effects of light and darkness on oxygen distribution and consumption in the cat retina. J. Gen. Physiol. 88:1986;521-542.
28. Linsenmeier R. A. Electrophysiological consequences of retinal hypoxia. Graefe's Arch. Clin. Exp. Ophthalmol. 228:1990;143-150.
29. Linsenmeier R. A., Braun R. D. Oxygen distribution and consumption in the cat retina during normoxia and hypoxemia. J. Gen. Physiol. 99:1992;177-197.
30. Marshall R. S., Rauth A. M. Oxygen and exposure kinetics as factors influencing the cytotoxicity of porfiromycin, a mitomycin C analogue, in Chinese hamster ovary cells. Cancer Res. 48:1988;5655-5659.
31. Maslim J., Valter K., Egensperger R., Hollander H., Stone J. Tissue oxygen during a critical development period controls the death and survival of photoreceptors. Invest. Ophthalmol. Vis. Sci. 38:1997;1667-1677.
32. Nakajima M., Yuge K., Senzaki H., Shikata N., Hirohiko M., Uyama M., Tsuchida A. Photoreceptor apoptosis induced by a single systemic administration of N-methyl-N-nitrosourea in the rat retina. Am. J. Pathol. 148:1996;631-641.
33. Nambu H., Yuge K., Nakajima M., Shikata N., Takahashi K., Miki H., Uyama M., Tsubura A. Morphologic characteristics of N-methyl-N-nitrosourea-induced retinal degeneration in C57BL mice. Pathol. International. 47:1997;377-383.
34. Nordsmark M., Overgaard M., Overgaard J. Pretreatment oxygenation predicts radiation response in advanced squamous cell carcinoma of the head and neck. Radiother. Oncol. 41:1996;31-39.
35. Olive P. L. Detection of hypoxia be measurement of DNA damage in individual cells from spheroids and murine tumours exposed to bioreductive drugs. 2. RSU. 1069. Br. J. Cancer. 71:1995;537-542.
36. O'Neill P., McNeill S. S., Jenkins T. C. Induction of DNA crosslinks in vitro upon reduction of the nitroimidazole-aziridines RSU-1069 and RSU-1131. Biochem. Pharmacol. 36:1987;1787-1792.
37. Overgaard J., Horsman M. R. Modification of hypoxia-induced radioresistance in tumors by the use of oxygen and sensitizers. Semin. Radiat. Oncol. 6:1996;10-21.
38. Palmer B. D., Wilson W. R., Atwell G. J., Schultz D., Xu X. Z., Denny W. A. Hypoxia-selective antitumor agents. 9. Structure-activity relationships for hypoxia-selective cytotoxicity among analogues of 5-[N,N-bis(2-chloroethyl)amino]-2,4-dinitrobenzamide. J. Med. Chem. 37:1994;2175-2184.
39. Parker R. F., Vincent P. W., Elliot W. L. Alkylating property of nitro-imidazole radiosensitizers is required for induction of murine retinal degeneration. Vet. Pathol. 33:1996;625.
40. Patterson A. V., Saunders M. P., Chinje E. C., Patterson L. H., Stratford I. J. Enzymology of tirapazamine metabolism: A review. Anti-Cancer Drug Des. 13:1998;541-573.
41. Patterson L.H. Rationale for the use of aliphatic N-oxides of cytotoxic anthraquinones as prodrug DNA binding agents: A new class of bioreductive agent. Cancer Metastasis Rev. 12:1993;119-134.
42. Pilcher G., Breider M., Pegg D. Single dose intravenous toxicity of CI-1010, a cytotoxic radiosensitizing nitroimidazole derivative, in rats. Fundam. Appl. Toxicol. 1996.
43. Pournaras C. J. Retinal oxygen distribution. Its role in the physiopathology of vasoproliferative microangiopathies. Retina. 15:1995;332-347.
44. Pournaras, C. J.1996. Autoregulation of ocular blood flow. In Ocular Blood Flow (H. J. Kaiser, J. Flammer, and P. Hendrickson, Eds.), pp. 40-50. Karger, Basel.
45. Rauth A. M., Melo T., Mistra V. Bioreductive therapies: An overview of drugs and their mechanisms of action. Int. J. Radiat. Oncol. Biol. Phys. 42:1998;755-762.
46. Rockwell S., Keyes S. R., Sartorelli A. C. Preclinical studies of porfiromycin as an adjunct to radiotherapy. Radiat. Res. 116:1988;100-113.
47. Schwartzman M. L., Masferrer J., Dunn M. W., McGiff J. C., Abraham N. G. Cytochrome P450, drug metabolising enzymes and arachadonic acid metabolism in bovine ocular tissues. Current Eye Res. 6:1987;623-630.
48. Sebolt-Leopold J. S., Elliot W. L., Showalter H. D., Leopold W. R. Rationale for the selection of PD 144872, the R isomer of RB 6145, for clinical development as a radiosensitizer. Proc. Am. Assoc. Cancer Res. 34:1993;362.
49. Siemann D. W., Hinchman C. A. Potentiation of cisplatin activity by the bioreductive agent tirapazamine. Radiother. Oncol. 47:1998;215-220.
50. Siim B. G., Atwell G. J., Wilson W. R. Oxygen dependence of the cytotoxicity and metabolic activation of 4-alkylamino-5-nitroquinoline bioreductive drugs. Br. J. Cancer. 70:1994;596-603.
51. Steinberg R. Monitoring communications between photoreceptors and pigment epithelial cells: Effects of "mild" systemic hypoxia. Invest. Opthalmol. Vis. Sci. 28:1987;1888-1904.
52. Stratford I. J., Workman P. Bioreductive drugs into the next mellenium. Anti-Cancer Drug Des. 13:1998;519-528.
53. Turley H., Comley M., Houlbrook S., Nozaki N., Kikuchi A., Hickson I. D., Gatter K., Haris A. L. The distribution and expression of the two isoforms of DNA topoisomerase II in normal and neoplastic human tissues. Br. J. Cancer. 75:1997;1340-1346.
54. Vinores S. A. Assessment of blood-retinal barrier integrity. Histol. Histopathol. 10:1995;141-154.
55. vonPawel J., von Roemeling R. Survival benefit from tirazone (tirapazamine) and cisplatin in advanced non-small cell lung cancer (NSCLC) patients: Final results from the international phase III CATAPULT 1 trial. Proc. Am. Soc. Clin. Oncol. 17:1998;454a.
56. Wang J., Beidermann K. A., Brown J. M. Repair of DNA and chromosome breaks in cells exposed to SR 4233 under hypoxia or to ionizing radiation. Cancer Res. 52:1992;4473-4477.
57. Whitmore G. F., Gulyas S. Studies on the toxicity of RSU-1069. Int. J. Radiat. Oncol. Biol. Phys. 12:1986;1219-1222.
58. Wilson W. R. Tumour hypoxia: Challenges for cancer chemotherapy. Waring M. J., Ponder B. A. J. Cancer Biology and Medicine. 1992;87-131 Kluwer, Lancaster.
59. Wilson W. R., Siim B. G., Moselen J. W., Pullen S. M. Quantitative oxygen dependence (K values) for bioreductive drug cytotoxicity. Proc. Am. Assoc. Cancer Res. 35:1994;634.
60. Wilson W. R., Tercel M., Anderson R. F., Denny W. A. Radiation-activated prodrugs as hypoxia-selective cytotoxins: Model studies with nitroarylmethyl quaternary salts. Anti-Cancer Drug Des. 13:1998;663-685.
61. Yuge K., Nambu H., Senzaki H., Nakao I., Miki H., Uyama M., Tsubura A. N-Methyl-N-nitrosourea-induced photoreceptor apoptosis in the mouse retina. In Vivo. 10:1996;483-488.